Nabity Jensen Investment Management Inc Cuts Stock Position in Pfizer Inc. $PFE

Nabity Jensen Investment Management Inc cut its holdings in Pfizer Inc. (NYSE:PFE) by 12.4% in the second quarter, HoldingsChannel reports. The firm owned 10,588 shares of the biopharmaceutical company’s stock after selling 1,497 shares during the quarter. Nabity Jensen Investment Management Inc’s holdings in Pfizer were worth $257,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Vanguard Group Inc. lifted its stake in shares of Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Pfizer by 6.8% in the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock valued at $1,579,340,000 after purchasing an additional 3,943,397 shares during the last quarter. Amundi lifted its stake in shares of Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Pfizer by 2.8% in the 1st quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after purchasing an additional 838,198 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in shares of Pfizer by 7.0% in the 1st quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company’s stock valued at $715,581,000 after purchasing an additional 1,846,436 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday. Finally, Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Pfizer has an average rating of “Hold” and an average target price of $28.12.

Pfizer Trading Up 6.8%

PFE opened at $25.46 on Wednesday. The stock’s fifty day moving average is $24.55 and its two-hundred day moving average is $24.11. The company has a market capitalization of $144.75 billion, a P/E ratio of 13.54, a PEG ratio of 0.77 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the business posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.